Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) insider Conor Kilroy sold 11,738 shares of the firm’s stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $7.02, for a total transaction of $82,400.76. Following the transaction, the insider directly owned 217,835 shares in the company, valued at $1,529,201.70. This represents a 5.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Conor Kilroy also recently made the following trade(s):
- On Tuesday, February 17th, Conor Kilroy sold 12,079 shares of Aura Biosciences stock. The shares were sold at an average price of $5.05, for a total transaction of $60,998.95.
Aura Biosciences Trading Down 0.4%
Shares of AURA stock opened at $7.06 on Friday. The stock has a market cap of $452.90 million, a P/E ratio of -3.94 and a beta of 0.35. Aura Biosciences, Inc. has a 1 year low of $4.34 and a 1 year high of $7.48. The stock has a 50 day simple moving average of $6.16 and a 200 day simple moving average of $5.92.
Institutional Investors Weigh In On Aura Biosciences
A number of hedge funds have recently made changes to their positions in AURA. Tower Research Capital LLC TRC boosted its holdings in shares of Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after acquiring an additional 2,104 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Aura Biosciences during the fourth quarter valued at about $59,000. Water Island Capital LLC acquired a new stake in shares of Aura Biosciences during the third quarter valued at about $64,000. 49 Wealth Management LLC bought a new stake in shares of Aura Biosciences during the third quarter worth about $66,000. Finally, Invesco Ltd. acquired a new position in shares of Aura Biosciences in the second quarter valued at approximately $76,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have recently commented on AURA. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Aura Biosciences in a research report on Monday, March 30th. Wall Street Zen raised shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Aura Biosciences in a research note on Friday, March 27th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.50.
View Our Latest Stock Analysis on AURA
About Aura Biosciences
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Recommended Stories
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
